Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose escalation of metformin versus addition of sitagliptin in type 2 diabetes inadequately controlled on metformin
ChiCTR2000031128Phase 4Recruiting
- Sponsor
- the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metformin and sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by the First Affiliated Hospital Division of Life Sciences and Medicine University of Science and Technology of China. Primary endpoint: HbA1c. Started Mar 2020; status: recruiting.
02
Drugs
metforminsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2000031128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031128.